CION Ameerpet
Chemotherapy has finished, the scans have improved, and now someone has suggested tablets you take at home for the next two years. If you have been searching PARP inhibitor ovarian cancer since that conversation, this page explains what this drug class does, whose disease it helps most, and where its limits honestly are.
A PARP inhibitor is not chemotherapy and it is not radiotherapy. It is a tablet or capsule taken at home, usually once or twice a day, started only after platinum-based chemotherapy has already cleared or shrunk the visible disease. Its job is not to attack a tumour you can see on a scan. Its job is to stop the cells that might be left behind from repairing themselves.
PARP is an enzyme your cells use to mend a very ordinary kind of DNA damage — a break in one strand of the double helix, of which every cell gets thousands a day. Block that enzyme and the small breaks build up, then turn into breaks across both strands the next time the cell divides. Healthy cells mend double-strand breaks with a backup system called homologous recombination, which depends on the BRCA1 and BRCA2 genes working properly. A cancer cell carrying a BRCA mutation has already lost that backup. Take away its remaining repair route and it has nowhere to go, so it dies. Your normal cells, which still have homologous recombination, carry on.
That mechanism has a name — synthetic lethality — and it explains everything else on this page. It explains why the benefit is largest in women with a BRCA mutation, why homologous recombination deficiency (HRD) testing exists at all, and why nobody should be started on this treatment before those results are back. The drug is aimed at a specific weakness. Where the weakness is absent, there is far less for it to exploit, and the honest conversation changes.
Taken at home, every day, alongside ordinary life. No cannula and no chemotherapy day unit — though there are monthly blood tests and real side effects to manage.
It is started once platinum-based chemotherapy has produced a complete or partial response. It is not a rescue treatment for disease that is still growing on treatment.
The target is not how fast the tumour grows but its inability to mend DNA. That is why a laboratory result decides this more than the size of what was removed.
In the SOLO-1 trial, women with newly diagnosed advanced ovarian cancer and a BRCA1 or BRCA2 mutation, who were in response after platinum-based chemotherapy, were randomly assigned to two years of PARP-inhibitor-class maintenance or to placebo. Maintenance reduced the risk of the disease progressing, or of death, by around 70% (hazard ratio 0.30). That single result moved this drug class out of the recurrence setting and into first-line treatment — and it is the reason BRCA testing is now done at diagnosis rather than years later, when it would be too late to change the plan. Source: Moore K et al., New England Journal of Medicine (2018); NCCN Ovarian Cancer guidelines.
This is the one point in ovarian cancer treatment where a single laboratory report changes the recommendation more than the stage does. Find your result in the left-hand column before you read anything else.
| Your test result | What the first-line trials showed | What it usually means for you |
|---|---|---|
| BRCA1 or BRCA2 mutation — inherited, or found in the tumour alone | The largest and most consistent benefit of any group: a long delay in recurrence, sustained well beyond the two years of treatment in long-term follow-up. | Maintenance is usually recommended once you are in complete or partial response after platinum-based chemotherapy. For most women in this group the decision is straightforward. |
| HRD-positive, no BRCA mutation found | A clear benefit, consistently smaller than in BRCA-mutated disease but well beyond chance. Trials in this group often paired maintenance with anti-angiogenic therapy. | Usually offered, sometimes as a combination. Worth a proper conversation about what the expected gain is in months, and what a year or more of daily tablets asks of you. |
| HRD-negative, or homologous recombination proficient | A modest delay in recurrence in the trials that included this group, without the striking effect seen where the repair defect is present. | A genuinely individual decision rather than an automatic one. Some women take it; others reasonably choose surveillance. Neither answer is wrong, and you should not be rushed. |
| Not tested yet | Every first-line trial selected or stratified patients by biomarker. There is no evidence base for starting blind. | Test first. Germline BRCA testing is recommended for everyone with epithelial ovarian cancer; tumour BRCA and HRD testing follow if the germline test is negative. |
| Disease that progressed during platinum-based chemotherapy | Maintenance is a strategy for holding on to a response. It was never tested as a treatment for disease that is still growing. | This is not the setting for it, and being told so is not bad news about you personally. The conversation moves to other systemic treatment options instead. |
*Germline BRCA testing is recommended for everyone diagnosed with epithelial ovarian cancer, regardless of age or family history — a substantial share of mutations turn up in women with no relevant family history at all. If it is negative, tumour BRCA and HRD testing on the surgical or biopsy specimen answer the next question.
The mechanics matter as much as the evidence. Most of what worries people before starting turns out to be logistics rather than biology — and the logistics are answerable.
Maintenance is treatment given when there is little or no visible disease left, with one aim: to keep it that way for longer. It is not a second course of chemotherapy, and it is not offered because something has gone wrong. It is offered because something has gone right and there is now something worth protecting.
The honest framing is that maintenance delays recurrence. In BRCA-mutated disease that delay can be very long, and a proportion of women remain free of recurrence years after the tablets have stopped. It is not a promise that the cancer will not return, and anyone who tells you otherwise is overselling it. See our wider guide to maintenance therapy and delaying recurrence.
Eligibility depends on being in complete or partial response at the end of platinum-based chemotherapy, judged on imaging and CA-125 together. That gate exists because the trials were built that way: every participant had already responded before randomisation, so the results only tell us what happens in women who have responded.
There is a second, more practical reason. This drug class acts on residual cells that are hard to see, not on bulky disease that is actively progressing. Starting it in the wrong setting would expose you to months of side effects for a benefit that was never demonstrated.
Germline BRCA1 and BRCA2 testing, from a blood or saliva sample, is recommended for everyone with epithelial ovarian cancer. If that is negative, the tumour tissue itself is tested for a BRCA mutation that arose in the cancer alone, and for homologous recombination deficiency.
These take time, which is why they should be ordered at diagnosis rather than at the end of chemotherapy. A common and avoidable problem is finishing six cycles and then waiting weeks for a result that decides the next two years. If testing has not been arranged for you, ask why at your next appointment.
In the first-line BRCA-mutated setting the standard plan is two years, which is how the defining trial was designed. Other first-line regimens run for up to three years, and some schedules continue until the disease progresses or the treatment can no longer be tolerated. Your oncologist should tell you which applies to you, in months, at the start rather than as you go along.
Stopping at the planned end point is not giving up. The fixed duration is what was tested, and the long-term follow-up showing sustained benefit came from women who stopped on schedule.
A full blood count before you start and then monthly, more often in the first few months. The commonest problems with this class are falling blood counts — anaemia above all, and lower platelet or white cell counts — along with nausea and fatigue that are usually worst in the first eight weeks and then settle.
Most of these are handled with a dose reduction or a short break rather than by stopping altogether, and a dose reduction does not mean the treatment has stopped working. There is also an uncommon but real long-term risk of a bone marrow disorder, which is one reason the blood counts keep being checked. The detail is on our page covering PARP inhibitor side effects and monitoring.
It can, and it is not a sign that you did anything wrong — maintenance shifts the odds and the timeline, it does not remove the possibility. Recurrence is usually picked up on a rising CA-125, on a routine scan, or occasionally because symptoms return.
The tablets are stopped and the conversation moves to treatment for recurrent disease, guided by how long you had been off platinum-based chemotherapy, where the disease has come back, how much of it there is, and how well you are. Returning to this class of treatment later is possible in some situations, but it is a more selective decision than it once was.
Long-term oral therapy is budgeted differently from inpatient chemotherapy, and it is the part of ovarian cancer treatment that most often surprises families months in. Ask three specific questions before you start: what the monthly cost is at the dose you will actually take, what your insurance policy or government scheme covers for oral cancer medicines as opposed to admissions, and what happens to that cover if the dose is later reduced.
Ask for the answer in writing and for the full planned duration, not for a single month. If you would like this worked through with your own reports and policy in front of you, request a cost estimation from our ovarian cancer treatment team in Hyderabad before treatment starts rather than after.
Most effects of this drug class are manageable and settle with a dose adjustment. A small number should be acted on the same day, and knowing which is which makes the treatment far easier to live with.
Bruises you cannot account for, bleeding gums, or a nosebleed that will not stop can mean a low platelet count. Ask for a blood count rather than waiting.
Any temperature above 38°C, or feeling suddenly unwell and shivery, needs a same-day call. A low white cell count lets ordinary infections move faster.
New breathlessness on stairs, a racing heart or unusual pallor usually means anaemia. It is common on this class, and very treatable once it is measured.
If you cannot keep the medicine down for more than a day, phone rather than skipping doses quietly. Timing and anti-sickness cover can nearly always be changed.
Persistent cough or breathlessness without an obvious infection is uncommon, but it should be checked promptly rather than managed at home.
Tiredness usually peaks early and then eases. Fatigue that deepens month after month is worth investigating rather than enduring.
None of these means the treatment has to stop. Almost all are handled with a blood test, a dose adjustment or a short break — but only if someone knows about them. Full detail on what to expect and when: PARP inhibitor side effects and monitoring.
Bring your BRCA or HRD report, your chemotherapy summary and your most recent scan. In 45 minutes a medical oncologist can tell you what the evidence actually predicts in your situation, and what it does not.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If your test results mean the benefit would be small, we will say so plainly rather than start you on two years of tablets.
Six steps, and the order genuinely matters. The commonest avoidable delay in this pathway is testing that was ordered too late to inform the decision it was meant to inform.
A histological diagnosis from surgery or a biopsy, with the subtype named. Maintenance of this kind is a question for epithelial ovarian, fallopian tube and primary peritoneal cancer — overwhelmingly high-grade serous disease. Make sure enough tissue is preserved for molecular testing later: a small request at the time, and an expensive omission afterwards.
A blood or saliva test, recommended for everyone with epithelial ovarian cancer regardless of family history. Send it early, because it takes weeks and because it also determines whether your sisters, daughters and brothers should be offered testing of their own. Genetic counselling accompanies it in both directions — before the sample and after the result.
Some BRCA mutations arise in the cancer alone and are invisible on a blood test. Where germline testing is negative, the tumour block is tested for a somatic BRCA mutation and for the broader repair defect described on our page explaining homologous recombination deficiency. This is the result that decides the middle rows of the table above.
In whichever order the disease dictates — surgery first with chemotherapy after, or chemotherapy first with interval surgery. Debulking and other gynaecologic-oncology surgery is coordinated with specialist partner centres, where it is performed and may be billed. Chemotherapy is delivered in-house at CION.
At the end of chemotherapy, a CT scan and a CA-125 establish whether you are in complete or partial response. This is the point at which maintenance either becomes an option or does not, and it is worth asking your oncologist to state the answer in those words rather than leaving it implied.
Baseline blood counts, a clear plan for how long you will take it, and monthly monitoring from then on. Expect the first eight weeks to be the hardest for nausea and fatigue, and expect a dose adjustment to be a normal event rather than a setback. Most women settle into a routine that fits around ordinary life.
*If you are reading this after chemotherapy has already finished and no BRCA or HRD testing has been done, it is not too late — but ask for it now rather than at the next review.
Two questions bring most women to a second opinion at this point. The first is whether this treatment is really worth two years of daily tablets and monthly blood tests. The second, asked more quietly, is whether it is being recommended because the evidence supports it in their particular case, or because it is simply what everyone is given now. Both deserve an unhurried hour and someone willing to answer the second question honestly.
Your first consultation at CION is free and runs to about 45 minutes. Bring the histopathology report, the germline BRCA result and any tumour BRCA or HRD report, your chemotherapy summary, and the end-of-treatment scan and CA-125. Much of the useful work is straightforward: reading your own results with you, saying which row of the table above you actually fall into, and being specific about what the expected benefit is and what it is not. Every case is discussed at a tumour board rather than decided by one doctor alone.
The division of care should be clear before you decide. Chemotherapy and maintenance therapy are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, together with genetic counselling, BRCA and HRD testing, nutrition support, survivorship care and long-term follow-up. Debulking and other gynaecologic-oncology surgery, HIPEC and PET-CT are coordinated with specialist partner centres, where they are performed and may be billed. That is stated upfront rather than left to be discovered when the bill arrives.
Free and unhurried. Long enough to read your BRCA and HRD reports with you and to say plainly how much benefit the evidence actually supports in your case.
Genetic counselling, germline BRCA testing and HRD testing are arranged through CION, and ordered at diagnosis rather than after chemotherapy has finished.
Monthly blood counts and reviews at whichever of our 35+ centres is closest to you, rather than repeat trips into one city hospital for a tablet you take at home.
Medical oncology, imaging and pathology review the maintenance decision together — including the cases where the honest answer is that the gain would be small.
Almost every headline figure for this drug class describes progression-free survival — the time before the cancer is seen to grow again. That is a real and meaningful benefit: months and sometimes years without recurrence, without treatment, and without the anxiety that surrounds both. It is not the same measurement as living longer overall, which takes far more years of follow-up to establish and is confounded by every treatment given afterwards. When someone quotes you a striking number, it is worth asking which of the two it is.
The second honest point is that a hazard ratio describes a group, not a person. A 70% reduction in the risk of progression does not mean any individual woman has a 70% chance of anything. It means that, across a large randomised population, the treated group reached recurrence considerably later than the untreated group. Some women in that treated group still recurred early. Some in the placebo group never did.
You will also find stage-specific ovarian survival percentages online, and they will frighten you more than they inform you. Most were compiled before biomarker-directed maintenance existed at all, they average across substages and across tumour subtypes that behave very differently, and they mix women who had complete surgical cytoreduction with women who did not. A figure built from a different era of treatment is not a forecast for a woman being offered treatment that did not exist when the figure was collected.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
One-year survival is not a cure rate and not a prediction for any individual. Stage, subtype, surgical outcome and your BRCA or HRD status all matter more to your own outlook.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
It blocks an enzyme called PARP that cells use to repair single-strand breaks in DNA. Those breaks happen constantly, and when they are not mended they turn into breaks across both strands the next time the cell divides. Healthy cells fix double-strand breaks using homologous recombination, a backup repair system that depends on the BRCA1 and BRCA2 genes. A cancer cell carrying a BRCA mutation has already lost that backup, so blocking its remaining repair route leaves it unable to survive division. Your normal cells still have homologous recombination and carry on as usual. This is why the treatment is aimed at a repair defect rather than at growth, and why a laboratory result rather than the stage decides who is offered it.
No, but the mutation is what makes the case strongest. The benefit is largest and most consistent in women with a BRCA1 or BRCA2 mutation, whether inherited or found only in the tumour. There is a second group without a BRCA mutation whose tumours still show homologous recombination deficiency on testing, and they gain clearly, though less. Where testing shows neither, the delay in recurrence seen in trials was modest, and the decision becomes genuinely individual rather than automatic. That is a conversation about months of expected benefit weighed against months of daily tablets and monitoring, and it is reasonable to decide either way.
In the first-line setting with a BRCA mutation, the standard plan is two years, because that is how the defining trial was designed and how the long-term benefit was demonstrated. Some other first-line regimens run for up to three years, and certain schedules continue until the disease progresses or the treatment can no longer be tolerated. Ask your oncologist which of these applies to you, in months, at the start rather than discovering it later. Reaching the planned end point and stopping is not giving up: the sustained benefit seen years afterwards came from women who completed a fixed course and then stopped on schedule.
It is not chemotherapy, and hair loss is not a typical effect of this drug class. Maintenance is an oral treatment taken at home, so there are no infusion appointments and no day-unit visits, though you will need a blood count roughly every month. The effects that do occur are different in character from chemotherapy: nausea, fatigue and falling blood counts, particularly anaemia, are the common ones, and they tend to be worst in the first two months and then settle. Most are managed with a dose adjustment or a short break rather than by stopping treatment altogether.
The commonest are anaemia, lower platelet or white cell counts, nausea and fatigue. Anaemia is the one that most often needs action, and it explains the monthly blood tests. Nausea usually responds to taking the dose with food, changing the time of day, or regular anti-sickness medication. Fatigue is real and typically peaks in the first eight weeks. A dose reduction is a routine part of this treatment and does not mean it has stopped working. There is also an uncommon but genuine long-term risk of a bone marrow disorder, which is another reason counts are monitored throughout. Our page on PARP inhibitor side effects and monitoring covers each of these in detail.
Maintenance shifts the timeline and the odds; it does not remove the possibility of recurrence. If the cancer returns while you are on treatment, it is usually detected by a rising CA-125, on a routine scan, or occasionally because symptoms come back. The tablets are stopped and the conversation moves to treatment for recurrent disease. What is offered next depends on how long it has been since platinum-based chemotherapy, where the disease has recurred, how much of it there is, and how well you are. Recurrence during maintenance does not mean you failed the treatment, and it does not mean nothing further can be done.
Possibly, but it is a more selective decision than it was a few years ago. This drug class was first used in recurrent disease that had responded again to platinum-based chemotherapy, and it delayed the next recurrence. As longer follow-up data arrived, the role in the recurrent setting narrowed, and it is now weighed more carefully against what else is available and against what treatment you have already had. If you were already on this class in the first-line setting, taking it again after recurrence is a different question with a much thinner evidence base. Bring your full treatment history to that conversation, because the sequence matters more than anything else.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house, which covers platinum-based chemotherapy and PARP-inhibitor-class maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, germline BRCA testing and HRD testing, nutrition support and long-term follow-up. Debulking and other gynaecologic-oncology surgery, HIPEC and PET-CT are coordinated with specialist partner centres, where they are performed and may be billed, and we say so upfront rather than leaving it to be discovered later. Every case is reviewed at a tumour board rather than decided by one doctor.